Literature DB >> 4005487

Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis.

F Brown, W Campbell, P J Mitchell, K Randall.   

Abstract

Criteria for distinguishing dopamine autoreceptor agonism from other mechanisms of inhibiting locomotion were examined, together with the relationship between inhibition of locomotion and dopamine synthesis. ED50 potencies to inhibit locomotion of mice were established for drugs from a number of categories. Spiperone 0.02 mg kg-1 significantly (P less than 0.05) reversed inhibition of locomotion by known dopamine agonists but not that by the other types of drug. Idazoxan antagonized inhibition of locomotion due to alpha 2-agonists but not dopamine agonists. RU 24926 (N-propyl-N,N-di[2-(3-hydroxyphenyl)ethyl]amine) was antagonized by both spiperone and idazoxan. Only for dopamine agonists was there good correlation (r = 0.97) between potencies to inhibit locomotion in mice and L-dihydroxyphenylalanine (L-DOPA) accumulation in the nucleus accumbens of rats treated with gamma-butyrolactone and 3-hydroxybenzylhydrazine. The specific dopamine D1-agonist, SK&F 38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine), was inactive in both tests at doses up to 10 mg kg-1. The mixed dopamine agonist/antagonist, (-)-3-(3-hydroxyphenyl)-N-propylpiperidine, commonly known as (-)-3-PPP, acted as a dopamine agonist in both tests but inhibited locomotion more potently than L-DOPA accumulation. The inhibitory effects of dopamine agonists on locomotion were not prevented by alpha-methyl-p-tyrosine pretreatment. The data suggest that spiperone-reversible inhibition of locomotion in mice is a good criterion for dopamine autoreceptor agonists. The receptors involved are affected by low doses of both dopamine agonists and antagonists and seem similar to those involved in the autoreceptor mediated inhibition of dopamine synthesis. However, inhibition of locomotion is not due simply to suppression of dopamine release brought about as a secondary consequence of effects on synthesis; a separate mechanism for inhibiting dopamine release is probably involved.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005487      PMCID: PMC1987050          DOI: 10.1111/j.1476-5381.1985.tb17379.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Evidence for dopamine receptors mediating sedation in the mouse brain.

Authors:  G Di Chiara; M L Porceddu; L Vargiu; A Argiolas; G L Gessa
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

2.  Do presynaptic autoreceptors control dopamine release?

Authors:  M Raiteri; A M Cervoni; R del Carmine; G Levi
Journal:  Nature       Date:  1978-08-17       Impact factor: 49.962

3.  Drug-induced changes in the release of 3 H-monoamines from field stimulated rat brain slices.

Authors:  L O Farnebo; B Hamberger
Journal:  Acta Physiol Scand Suppl       Date:  1971

Review 4.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

5.  Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels.

Authors:  C Euvrard; L Ferland; T Di Paolo; M Beaulieu; F Labrie; C Oberlander; J P Raynaud; J R Boissier
Journal:  Neuropharmacology       Date:  1980-04       Impact factor: 5.250

6.  Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors.

Authors:  J R Walters; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

7.  Determination of picomole amounts of dopamine, noradrenaline, 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindolacetic acid in nervous tissue after one-step purification on Sephadex G-10, using high-performance liquid chromatography with a novel type of electrochemical detection.

Authors:  B H Westerink; T B Mulder
Journal:  J Neurochem       Date:  1981-04       Impact factor: 5.372

8.  The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland.

Authors:  K A Wreggett; A De Léan
Journal:  Mol Pharmacol       Date:  1984-09       Impact factor: 4.436

9.  The central effects of a novel dopamine agonist.

Authors:  P E Setler; H M Sarau; C L Zirkle; H L Saunders
Journal:  Eur J Pharmacol       Date:  1978-08-15       Impact factor: 4.432

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  14 in total

1.  On the selectivity and specificity of the antagonism of apomorphine-induced suppression of exploration by sulpiride.

Authors:  L Ståhle; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Do autoreceptors mediate dopamine agonist--induced yawning and suppression of exploration? A critical review.

Authors:  L Ståhle
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  B-HT 920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors.

Authors:  N E Andén; M Grabowska-Andén
Journal:  J Neural Transm Gen Sect       Date:  1990

4.  Repeated 7-OH-DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine.

Authors:  B A Mattingly; S E Fields; M S Langfels; J K Rowlett; P M Robinet; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

5.  Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors:  J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm Gen Sect       Date:  1990

7.  Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats.

Authors:  A Guyon; F Assouly-Besse; G Biala; A J Puech; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behaviour in rats.

Authors:  L Ståhle; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors.

Authors:  H Nissbrandt; G Engberg; H Wikström; T Magnusson; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

10.  Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.

Authors:  T B Mulder; J B de Vries; D Dijkstra; J W Wiechers; C J Grol; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.